ATG5 and melanoma: Importantly, downregulation of both ATG5 and ATG7 correlates with a less favourable outcome for patients, suggesting the potential use of ATG5 and ATG7 levels as prognostic markers in melanoma in order to recognize the more aggressive, metastatic phenotype.